Revenues at Ampac Fine Chemicals rose 55% to $30.8m in its Q3 2011 compared to 2010. The company attributed this to increases in revenues from core products in its key therapeutic areas including a 139% rise in revenues from anti-viral products.
Seeking Alpha
Monday, 15 August 2011
Fine chemicals revenues rise at Ampac
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment